HK Stock MarketDetailed Quotes

09939 KINTOR PHARMA-B

Watchlist
  • 0.860
  • +0.020+2.38%
Market Closed Mar 28 16:08 CST
384.85MMarket Cap-328P/E (TTM)

About KINTOR PHARMA-B Company

We are an innovative drug company in clinical development in China dedicated to addressing diseases that do not meet clinical needs, particularly androgen receptor-related (or AR-related) diseases. We are committed to being a leading company in the research, development and commercialization of innovative therapies. We have developed seven clinical-stage drugs under development. frethane (KX-826) Frethane (KX-826) is an AR antagonist. We are currently developing furatane as a potential first-of-its-kind topical treatment for androgenic alopecia (AGA) and acne. AR-PROTAC compound (GT20029) GT20029 is an AR-PROTAC compound for external use developed using the Group's proprietary PROTAC platform. We are currently developing GT20029 to treat hair loss and acne. procluramide (GT0918) Pucluramide (GT0918) has the potential to become a second-generation AR antagonist of the best drug in its class. We are currently developing proclomide to treat COVID-19, mCRPC, and AR+ metastatic breast cancer. HedgeHog/smO inhibitors (GT1708F) The hedgehog/smo inhibitor (GT1708F) is an inhibitor of the hedgehog signal transduction pathway. We are currently developing GT1708F mainly for the treatment of idiopathic pulmonary fibrosis (IPF) and hematological tumors. Ditoxetyl (GT0486) Ditosetil (GT0486) is a PI3K/mTOR signaling pathway inhibitor and is a second-generation mTOR inhibitor. We are currently developing GT0486 mainly for treating metastatic solid tumors such as breast cancer, prostate cancer, and hepatocellular carcinoma (HCC). ALK-1 antibody (GT90001) The ALK-1 antibody is a new anti-angiogenesis inhibitor that we obtained exclusive global approval from Pfizer in 2018 and is a new biological target for the world. We are developing ALK-1 antibodies to treat metastatic HCC and various solid tumors. PD-L1/TGF-β (GT90008) PD-L1/TGF-beta (GT90008) is a double target antibody composed of a PD-L1 antagonist antibody and a TGF-beta extracellular domain. It has high activity of simultaneously inhibiting PD-L1 and TGF-beta. It has the potential to treat a variety of solid tumors, including non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-related tumors (such as cervical cancer), and may be the best drug of its kind.

Company Profile

Symbol09939
Company NameKINTOR PHARMA-B
ISINKYG5273B1077
Listing Date05/22/2020
Issue Price20.15
Shares Offered92.35M share
Founded05/16/2018
RegistrationCayman Islands
ChairmanYouzhi Tong
SecretaryWeichao\zhangmingming Huang
Audit InstitutionPricewaterhouseCoopers
Company CategoryOverseas registration of Mainland Individuals control
Registered OfficeCricket Square Hutchins Drive, PO Box 2681 Grand Cayman, KY1-1111 Cayman Islands
Head Office and Principal Place of BusinessRoom 2007, 20th Floor, Tower 2, Gateway Tower, Harbour City, Kowloon, Hong Kong
Fiscal Year Ends12-31
Employees225
MarketHong Kong motherboard
Phone(852)26338966
Fax(0512)62956309
EmailIR@kintor.com.cn
Business Kaituo Pharmaceutical Co., Ltd. is a clinical-stage novel drug developer focusing on the research of cancer drugs and drugs for other androgen receptor (AR) related diseases. The company's main drug under development is procluramide. The drug is undergoing phase III clinical trials for metastatic castration-resistant prostate cancer (mCRPC) in China. The company's clinical-stage drugs also include a phase II small-molecule drug in development, pyrilutamide, a phase II monoclonal antibody in development, ALK-1, a phase I mTOR inhibitor detorsertib, and GT1708F, a HedgeHog signal transduction pathway inhibitor.

Company Executives

  • Name
  • Position
  • Salary
  • Youzhi Tong
  • Executive Director,Authorized Representative,Remuneration Committee Member,Chairman of the Board,CEO,Nomination Committee Chairman
  • --
  • Weipeng Gao
  • Non-Executive Director
  • --
  • Min Xu
  • Independent Non-Executive Director,Nomination Committee Member,Remuneration Committee Chairman,Audit Committee Member
  • --
  • Huaiyan Yang
  • Independent Non-Executive Director,Audit Committee Chairman,Nomination Committee Member
  • --
  • Xiang Ni
  • Chief Medical Officer,Executive Director
  • --
  • Chengwei Liu
  • Non-Executive Director,Audit Committee Member
  • --
  • Mingming Zhang
  • Authorized Representative,CFO,Joint Company Secretary
  • --
  • Liang Tong
  • Remuneration Committee Member,Independent Non-Executive Director
  • --
  • Ruo Xu
  • VP
  • --
  • Geqi Wei
  • Non-Executive Director
  • --
  • Weichao Huang
  • Authorized Representative,Company Secretary
  • --
  • Qun Lu
  • Executive Director
  • --
  • Juping Shen
  • Deputy GM
  • --
  • Jiawen Han
  • Vice President of Business Development
  • --
  • Jie Chen
  • Deputy GM
  • --
  • Zhihua Ren
  • Vice President - Director of the New Drug Research Institute
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg